Pharmail

New porous silica structure overcomes drug solubility challenges

With an increasing number of drug candidates failing in development, the pharmaceutical industry is facing a shortage of new drugs. Poor bioavailability causes over 40% of these failures, often due to low solubility. Today, developers are faced with this issue in over 90% of their projects.

While there are technologies to address this, each comes with pros and cons and with no universal solution. At Merck, we believe bimodal silica is the most promising drug carrier to enhance bioavailability of poorly-water soluble drugs.

Studies have shown that bimodal silica improves performance for numerous APIs in-vitro and in-vivo and as a result, will benefit NCE development projects where low solubility is an issue. As more patents expire, reformulation of currently marketed drugs will enhance lifecycle management. This new tool can also be used to recover former drug candidates which failed due to low solubility, and to introduce alternative solutions for established drugs in the case of generic APIs with solubility issues.

To discover how this material can overcome drug solubility challenges in oral formulations, check out our recent webinar.

To watch, please click here

In This Same Issue:

• ChromaTALK™ moves to LinkedIn®
• Optimize your formulation with synthetic lipids
• Supporting your process: risk assessment guidelines on excipients

Tweet